Back to News
Market Impact: 0.2
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy from Neutral
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 6, 2026, HC Wainwright & Co. upgraded Crescent Biopharma from Neutral to Buy. The article also notes the firm had downgraded the stock from Buy to Neutral on June 1, 2026; the text provided ends before giving further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
CBIO0.55
More News
- JPMorgan and Deutsche Bank just upgraded Brazilian stocks. How to trade them
- GIC Private Ltd, Medline 10% owner, sells over $721m in shares
- Meta may ditch the idea of a cloud business for Muse. We think that’s a good trade
- Why is Telix Pharmaceuticals stock rallying today?
- A new analyst call on Home Depot reflects our feeling on what to do with the stock
- Why is Broadcom stock rallying today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Financial Research Benchmarks: What the Scores Mean
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper